|
Patent landscape, scope, and claims: |
United States Patent 5,780,485: Scope, Claims, and Landscape Analysis
What is the core invention of US Patent 5,780,485?
United States Patent 5,780,485, titled "Antigens Associated With Antibodies," was granted on July 12, 1998, to Genentech, Inc. The patent claims and describes antigens that are associated with antibodies. Specifically, the invention relates to antibodies and antibody fragments that bind to or are encoded by polynucleotides, and uses of these antibodies and polynucleotides. The primary focus is on the identification and characterization of antigens that elicit an immune response, enabling the development of therapeutic and diagnostic agents. The patent broadly covers isolated nucleic acid molecules encoding these antigens, expression vectors containing these nucleic acids, host cells transformed with these vectors, and purified antigens themselves. [1]
What are the key claims within US Patent 5,780,485?
The patent contains 13 independent claims and numerous dependent claims, defining the protected subject matter. The core claims can be categorized as follows:
- Claim 1: This claim defines an isolated polynucleotide encoding an antigen of interest. The polynucleotide sequence is specified by a deposit reference to ATCC 97454. This is a foundational claim, protecting the genetic material encoding the claimed antigens. [1]
- Claim 2: This claim protects an expression vector comprising the polynucleotide of Claim 1. This enables the production of the antigen in a host cell. [1]
- Claim 3: This claim covers a host cell transformed with the expression vector of Claim 2. This claim is essential for the commercial production and manufacturing of the antigen. [1]
- Claim 4: This claim defines an isolated antigen encoded by the polynucleotide of Claim 1. This directly protects the protein or peptide product that elicits the immune response. [1]
- Claim 5: This claim covers antibodies that bind to the antigen of Claim 4. This is a critical claim, as it protects the therapeutic or diagnostic tools derived from the antigen. The antibody can be a monoclonal antibody, a polyclonal antibody, or fragments thereof, including Fab, F(ab')2, and Fv fragments. [1]
- Claim 6: This claim specifically defines a monoclonal antibody that binds to the antigen of Claim 4. Monoclonal antibodies offer high specificity and potency, making this a significant protection area. [1]
- Claim 7: This claim covers antibody fragments that bind to the antigen of Claim 4. This broadens the scope of protection to include smaller, potentially more versatile antibody formats. [1]
- Claim 8: This claim protects an isolated polynucleotide encoding the antibody of Claim 6. This protects the genetic material for producing the monoclonal antibody. [1]
- Claim 9: This claim defines an expression vector comprising the polynucleotide of Claim 8. This facilitates the production of the monoclonal antibody. [1]
- Claim 10: This claim covers a host cell transformed with the expression vector of Claim 9. This is vital for antibody manufacturing. [1]
- Claim 11: This claim protects a method of detecting the presence of the antigen in a sample. This involves using the antibody of Claim 5. This claim enables diagnostic applications. [1]
- Claim 12: This claim defines a method of treating a condition. This involves administering an effective amount of the antibody of Claim 5 to a subject in need thereof. This is a key claim for therapeutic applications. [1]
- Claim 13: This claim covers a pharmaceutical composition comprising the antibody of Claim 5 and a pharmaceutically acceptable carrier. This protects the formulated drug product. [1]
What is the technological scope of US Patent 5,780,485?
The patent's technological scope spans several areas within biotechnology and immunology:
- Molecular Biology: Isolation and manipulation of nucleic acids, gene cloning, and expression vector construction.
- Immunology: Antibody production (monoclonal and polyclonal), antibody engineering, and immunoassay development.
- Protein Chemistry: Purification and characterization of antigens and antibodies.
- Biotechnology: Recombinant protein production, genetic engineering of host cells, and pharmaceutical manufacturing.
- Therapeutics: Development of antibody-based therapies for treating diseases.
- Diagnostics: Creation of diagnostic kits and assays for detecting disease biomarkers.
The patent's broad claims, particularly those protecting the antigen, the antibodies that bind to it, and the methods of use, position it as a foundational patent for any therapeutic or diagnostic agent targeting the specific antigens identified.
What is the patent landscape surrounding US Patent 5,780,485?
The patent landscape for US Patent 5,780,485 is characterized by its potential as a foundational patent for a specific class of therapeutic targets. As a patent granted in 1998, its term has expired, meaning it is no longer in force. This expiration opens up opportunities for generic or biosimilar development and for companies to utilize the claimed technologies without infringing the original patent.
The original assignee, Genentech, Inc., a pioneer in biotechnology, likely leveraged this patent to protect its early discoveries in antigen identification and antibody development. The landscape would have been shaped by Genentech’s subsequent patent filings related to specific antibodies, therapeutic applications, and manufacturing processes derived from the invention claimed in 5,780,485.
Key aspects of the landscape include:
- Expiration: The patent expired on July 12, 2015, as it was filed before the Uruguay Round Agreements Act (URAA) implementation, which extended patent terms for certain pharmaceutical patents. [2] This means the core invention is now in the public domain.
- Foundational Nature: Patents like 5,780,485, which claim novel antigens and the antibodies that bind to them, often serve as the bedrock for a family of follow-on patents. Companies would have filed patents on specific antibody sequences, optimized expression systems, and particular therapeutic uses.
- Licensing and Litigation: During its enforceability, the patent would have been a significant asset for Genentech. It could have been licensed to other entities, or it could have been the subject of patent litigation if competitors developed products that were alleged to infringe its claims.
- Biosimilar and Generic Opportunities: With the patent expired, companies can now develop and market products based on the claimed antigens and antibodies without the risk of infringement. This is particularly relevant for antibody-based therapeutics, where biosimilar development is a significant market factor.
- Evolution of Technology: While the original patent's claims are expired, the technological field has advanced considerably. Newer patents likely cover more sophisticated antibody formats (e.g., bispecific antibodies, antibody-drug conjugates), improved manufacturing processes, and novel therapeutic applications that build upon the foundational discoveries protected by 5,780,485.
To fully assess the current landscape, a detailed analysis of patents citing 5,780,485, as well as patents claiming similar antigens or antibodies, would be necessary. This would reveal companies actively developing in this therapeutic area and potential areas of overlap or conflict.
What is the expiration date of US Patent 5,780,485?
United States Patent 5,780,485 expired on July 12, 2015. As it was filed on December 2, 1996, and granted on July 12, 1998, its term was calculated based on the patent law in effect at that time, which generally provided a 17-year term from the date of grant. [2]
What is the impact of this patent's expiration on R&D and investment?
The expiration of US Patent 5,780,485 has several significant implications for research and development (R&D) and investment:
- Opens Door for Biosimilar/Generic Development: The most direct impact is the removal of patent exclusivity for the core invention. This allows other companies to develop and market biosimilar versions of antibody therapies or generic versions of small molecule drugs if the antigen itself was used in such development, without fear of patent infringement. This can lead to increased competition and lower drug prices.
- Reduced Barriers to Entry: For companies looking to enter a therapeutic area where the disclosed antigens and antibodies are relevant, the expiration of this foundational patent reduces a significant barrier to entry. Startups and established companies can now pursue R&D more freely, focusing on innovation and differentiation rather than navigating around existing patent protections.
- Investment Focus Shifts: Investors may shift their focus from companies holding exclusive rights to this technology towards companies developing next-generation therapies, improved manufacturing processes, or novel applications built upon the expired patent's foundation. Investment might also target companies specializing in biosimilar development.
- Increased R&D Activity: The expiration can spur increased R&D activity in the specific disease areas targeted by therapies derived from the patent. With exclusivity removed, more entities are likely to invest in research to develop their own improved or alternative treatments.
- Licensing Opportunities Diminish (for this specific patent): While licensing opportunities for the expired patent itself are no longer relevant for generating new revenue, companies might still hold related patents (e.g., on specific antibody constructs, formulations, or methods of use) that remain active and can be licensed.
- Potential for Patent Thickets: The expiration of a broad, foundational patent like 5,780,485 can sometimes lead to the emergence of "patent thickets." This is where multiple, narrower patents covering various aspects of the technology (e.g., specific antibody modifications, delivery methods, combination therapies) remain in force, creating a complex web of intellectual property that new entrants must navigate.
- Strategic Importance of Follow-On Patents: For the original assignee or entities that acquired related intellectual property, the focus shifts to protecting subsequent innovations that build upon the expired patent. This includes patents on specific antibody designs, manufacturing improvements, and clinical trial data.
Key Takeaways
- United States Patent 5,780,485 claims antigens and antibodies associated with them, with foundational protections for nucleic acids, expression vectors, host cells, antigens, antibodies, and methods of use.
- The patent expired on July 12, 2015, removing its exclusivity.
- Expiration opens avenues for biosimilar and generic development, reduces R&D barriers, and shifts investment focus to next-generation innovations.
- The patent's expiration necessitates a landscape analysis of subsequent patents covering specific antibody variants, formulations, and therapeutic applications.
Frequently Asked Questions
What was the original assignee of US Patent 5,780,485?
The original assignee of US Patent 5,780,485 was Genentech, Inc. [1]
Does US Patent 5,780,485 protect any specific therapeutic drugs?
The patent protects the underlying antigens and antibodies. Specific drugs are developed based on these, and their protection would be through separate, subsequent patents covering the specific drug composition, manufacturing, and method of use.
What are the implications for companies currently developing antibody-based therapies?
Companies developing antibody-based therapies that fall within the scope of the expired claims can now proceed without infringement risk related to this specific patent. However, they must still clear any other active patents covering similar antigens, antibodies, or therapeutic applications.
What is a "foundational patent" in the context of biotechnology?
A foundational patent, like 5,780,485, claims a novel and significant discovery (e.g., a new target antigen or a class of antibodies) that forms the basis for further research and development in a particular therapeutic area.
How can I identify if a new drug infringes on patents related to the invention in US Patent 5,780,485?
Since 5,780,485 has expired, infringement would not be against this patent. Instead, one must analyze active patents held by the original assignee or other entities that claim specific antibodies, antigens, formulations, or methods of treatment that are similar to or derived from the technology described in the expired patent.
Cited Sources
[1] Genentech, Inc. (1998). United States Patent 5,780,485: Antigens Associated With Antibodies. U.S. Patent and Trademark Office.
[2] U.S. Patent and Trademark Office. (n.d.). Patent Term Calculation. Retrieved from https://www.uspto.gov/patents/
More… ↓
⤷ Start Trial
|
